Argenx has a second FDA approval for FcRn inhibitor Vyvgart Hytrulo, adding new indication rare autoimmune disease CIDP.

The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).